1h Free Analyst Time
The CAR T-Cell therapy market is forecasted to grow by USD 1,999 mn during 2022-2027, accelerating at a CAGR of 13.44% during the forecast period. The report on the CAR T-Cell therapy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing awareness regarding CAR T-Cell therapy, the increasing prevalence of blood cancer, and the increasing incidence of hematological malignancies.
The CAR T-Cell therapy market is segmented as below:
By End-user
- Hospitals
- Cancer treatment centers
By Type
- CD19
- CD22
- BCMA
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the CAR T-Cell therapy market covers the following areas:
- CAR T-Cell therapy market sizing
- CAR T-Cell therapy market forecast
- CAR T-Cell therapy market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Exhibits:
Executive Summary
The publisher recognizes the following companies as the key players in the global CAR T-Cell therapy market: ACROBIOSYSTEMS INC., Allogene Therapeutics Inc., Autolus Therapeutics plc, Bristol Myers Squibb Co., Celyad Oncology SA, Eli Lilly and Co., Fate Therapeutics Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Les Laboratoires Servier SAS, Merck KGaA, Miltenyi Biotec B.V. and Co. KG, Noile Immune Biotech Inc., Novartis AG, Pfizer Inc., Sangamo Therapeutics Inc., Sorrento Therapeutics Inc., TCR2 Therapeutics Inc., and Fortress Biotech Inc.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is the rising number of product approvals and clinical trials related to car t- cell therapy.'
According to the report, one of the major drivers for this market is the growing awareness regarding car t-cell therapy.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ACROBIOSYSTEMS INC.
- Allogene Therapeutics Inc.
- Autolus Therapeutics plc
- Bristol Myers Squibb Co.
- Celyad Oncology SA
- Eli Lilly and Co.
- Fate Therapeutics Inc.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Johnson and Johnson Services Inc.
- Les Laboratoires Servier SAS
- Merck KGaA
- Miltenyi Biotec B.V. and Co. KG
- Noile Immune Biotech Inc.
- Novartis AG
- Pfizer Inc.
- Sangamo Therapeutics Inc.
- Sorrento Therapeutics Inc.
- TCR2 Therapeutics Inc.
- Fortress Biotech Inc.
